AIM ImmunoTech Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
AIM NYSE American 2830 aimimmuno.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for AIM ImmunoTech Inc.

AIM ImmunoTech Secures Broad U.S. Patent for Rintatolimod (Ampligen®) Used in Combination with Pembrolizumab (Keytruda®), Expanding Oncology IP Protection for Ampligen Through 2039 - Aug 31st, 2026 6:51 am
AIM ImmunoTech Participates in the Virtual Investor ‘Why Now’ On-Demand Conference - Aug 27th, 2026 7:01 am
AIM ImmunoTech CEO Highlights Biodefense and Military Force Protection in Newly Published ‘Breaking Defense’ Article - Aug 12th, 2026 6:44 am
AIMIA DECLARES PREFERRED SHARE DIVIDENDS - Aug 11th, 2026 5:00 am
AIMIA REPORTS SECOND QUARTER 2026 RESULTS - Aug 11th, 2026 4:00 am
AIM ImmunoTech Ahead of Schedule on ‘Last Dose’ DURIPANC Critical Clinical Inflection Point - Aug 3rd, 2026 6:33 am
Zacks.com featured highlights include AIM ImmunoTech, Hasbro, Fox, Cencora and Intuitive Surgical - Jul 24th, 2026 6:04 am
Bet on 5 Top-Ranked Stocks With Rising P/E - Jul 23rd, 2026 6:25 am
AIM ImmunoTech Announces Release of New CEO Corner Segment Highlighting Growing Momentum Across Pancreatic Cancer Program - Jul 7th, 2026 7:03 am
AIMIA PROVIDES UPDATE ON ITS SHARE BUYBACKS FOR JUNE - Jul 2nd, 2026 5:00 am
AIM ImmunoTech Accelerates Toward Potential Pivotal Pancreatic Cancer Program as Ampligen Continues to Advance Through Key Clinical Milestones - Jun 24th, 2026 6:29 am
AIM ImmunoTech to Present in the Webull Corporate Connect Webinar Series - Jun 22nd, 2026 6:45 am
AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer - Jun 18th, 2026 7:01 am
Bet on 5 Top-Ranked Stocks With Rising P/E for Solid Returns - Jun 18th, 2026 6:00 am
AIM ImmunoTech Regains NYSE American Compliance, Company Resolves Stockholder Equity Deficiency - Jun 15th, 2026 6:01 am
AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market under NYSE American Rules - Jun 9th, 2026 7:29 am
AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer - Jun 8th, 2026 6:33 am
AIM ImmunoTech Releases Virtual Investor ‘What This Means’ Video Segment Discussing Ampligen’s Potential in Ebola Virus Disease Preparedness - Jun 4th, 2026 6:55 am
AIM Stock Soars Over 200% As Pancreatic Cancer Trial Hits Enrollment Milestone Early — CEO Sees 'Value-Inflection Period' Ahead - Jun 1st, 2026 8:19 am
AIM ImmunoTech Completes Phase 2 DURIPANC Enrollment Milestone Ahead of Schedule, Advancing Ampligen Toward Critical Pancreatic Cancer Clinical Milestones - Jun 1st, 2026 6:58 am